Cantor Fitzgerald Weighs in on Nuvalent FY2025 Earnings

Nuvalent, Inc. (NASDAQ:NUVL) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Nuvalent in a note issued to investors on Thursday, October 16th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($5.26) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $135.00 price target on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. Cantor Fitzgerald also issued estimates for Nuvalent’s FY2026 earnings at ($5.87) EPS.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings results on Thursday, August 7th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.04). During the same quarter in the prior year, the business posted ($0.88) EPS.

Other analysts have also issued research reports about the stock. Wedbush restated an “outperform” rating and set a $115.00 price target on shares of Nuvalent in a research report on Monday, September 8th. Guggenheim assumed coverage on shares of Nuvalent in a research report on Thursday, September 4th. They set a “buy” rating and a $122.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $130.00 price target (up previously from $110.00) on shares of Nuvalent in a research report on Tuesday, June 24th. Robert W. Baird raised their price target on shares of Nuvalent from $105.00 to $112.00 and gave the company an “outperform” rating in a research report on Wednesday, June 25th. Finally, Leerink Partners raised their price target on shares of Nuvalent from $125.00 to $140.00 and gave the company an “outperform” rating in a research report on Tuesday, June 24th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $120.00.

Nuvalent Stock Performance

NUVL stock opened at $97.97 on Monday. The firm has a market cap of $7.06 billion, a PE ratio of -19.99 and a beta of 1.30. The firm’s fifty day moving average is $80.78 and its 200 day moving average is $77.26. Nuvalent has a one year low of $55.53 and a one year high of $104.44.

Insider Activity at Nuvalent

In related news, insider Henry E. Pelish sold 14,205 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $90.04, for a total transaction of $1,279,018.20. Following the transaction, the insider directly owned 65,963 shares in the company, valued at approximately $5,939,308.52. The trade was a 17.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Alexandra Balcom sold 1,683 shares of the business’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $85.57, for a total transaction of $144,014.31. Following the transaction, the chief financial officer owned 61,734 shares in the company, valued at $5,282,578.38. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 191,771 shares of company stock worth $16,298,129 in the last ninety days. 10.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Nuvalent

A number of institutional investors and hedge funds have recently bought and sold shares of NUVL. CWM LLC boosted its position in Nuvalent by 588.5% during the first quarter. CWM LLC now owns 420 shares of the company’s stock worth $30,000 after acquiring an additional 359 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in Nuvalent during the first quarter worth about $38,000. Covestor Ltd boosted its position in Nuvalent by 705.7% during the first quarter. Covestor Ltd now owns 983 shares of the company’s stock worth $70,000 after acquiring an additional 861 shares during the last quarter. Persistent Asset Partners Ltd acquired a new position in Nuvalent in the 2nd quarter valued at about $88,000. Finally, Farther Finance Advisors LLC boosted its holdings in Nuvalent by 9,230.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company’s stock valued at $93,000 after purchasing an additional 1,200 shares during the last quarter. 97.26% of the stock is currently owned by institutional investors and hedge funds.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.